보고서 요약(국문)

시장 개요
전 세계 선양낭성암 시장은 2022년 2억 2,430만 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 5.6%의 성장률을 보이며 2030년에는 3억 4,460만 달러에 이를 것으로 예상됩니다. 개인 맞춤형 의학으로의 전환과 같은 추세가 전 세계 선양낭성암 시장 성장을 주도할 것으로 전망됩니다.
전 세계 선양낭성암(ACC) 시장은 최근 몇 년간 크게 성장했으며, 이러한 상승세는 지속될 것으로 예상됩니다. 표적 치료제, 새로운 면역 치료제 및 RNA 치료제의 등장과 같은 여러 주요 트렌드의 영향으로 시장은 전환기를 맞고 있습니다.
또한, 선양낭성암의 유병률 증가, 진단 기술의 발전, 연구 개발 활동에 대한 투자 확대 등이 선양낭성암 시장 규모 확대를 견인하고 있습니다. 진단 기술의 발전으로 선양낭성암의 발견 및 진단이 향상됨에 따라 북미 지역에서 수요가 증가하고 있으며, Ayala Pharmaceuticals, Amgen, CureVac AG 등 주요 경쟁업체들이 시장에서 활발하게 활동하고 있습니다.

시장 동향
선양낭성암 발병률 증가가 시장 성장을 견인할 전망
선양낭성암 발병 건수 증가는 선양낭성암 시장 확장의 주요 동인입니다. 이는 질병에 대한 인식이 높아짐에 따라 발병 사례가 증가했기 때문입니다. 예를 들어, 미국 임상종양학회(ASCO)의 2023년 보고서에 따르면 미국에서는 매년 약 1,300명이 이 암 진단을 받았습니다.
또한, 선양낭성암은 여성에게서 가장 흔하게 발생하며 전체 사례의 60%를 차지합니다. 이러한 발생률 증가로 인해 새로운 치료법을 발견하고 기존 약물을 개선하기 위한 연구 개발에 더욱 중점을 두고 있습니다. 따라서 이러한 질환의 유병률 증가는 예측 기간 동안 시장 성장을 견인할 것입니다.
임상 시험 증가가 시장 성장을 촉진할 것입니다.
선양낭성암 치료 및 진단에 대한 임상 시험의 증가는 이 시장의 주요 성장 동력입니다. 임상 시험은 새로운 치료법과 진단법을 발견하는 데 중요한 역할을 하여 환자의 치료 결과를 개선합니다. 또한, 이러한 임상 시험에서 생성된 데이터는 연구를 촉진하고 국제 협력을 증진하는 중요한 통로가 됩니다.
예를 들어, 메모리얼 슬론 케터링 암센터는 머크 샤프앤도메 LLC 및 에자이 Inc.와 협력하여 2019년 12월에 임상 시험을 시작했습니다. 이 시험의 주요 목적은 진행성 선양낭성암(ACC) 환자를 대상으로 렌바티닙과 펨브롤리주맙과 같은 약물의 효과와 안전성을 평가하는 것입니다. 현재 임상 2상 시험이 진행 중이며, 2023년 12월 완료 예정입니다. 따라서 임상 시험 건수 증가로 인해 향후 시장 성장이 기대됩니다.
선양낭성암 치료의 높은 비용이 시장 성장을 저해할 수 있습니다.
선양낭성암 치료에는 수술, 표적 치료제와 같은 약물 치료가 포함되는데, 이러한 치료는 상대적으로 비용이 많이 들 수 있습니다. 이로 인해 선양낭성암 환자들이 첨단 치료를 받는 데 어려움을 겪고 있습니다. 예를 들어, 선양낭성암 치료에 사용되는 면역항암제의 비용은 많은 환자에게 매우 부담스러워 잠재적으로 유익한 치료 옵션에 대한 접근성을 제한하고 있습니다.
세분화 분석
전 세계 선양낭성암 시장은 지역, 약물 종류, 치료법, 유통 채널 및 지역별로 세분화됩니다.

수술 부문은 우수한 효과 덕분에 선양낭성암 시장 점유율의 약 34.6%를 차지했습니다.
수술 부문은 선양낭성암에 대한 효과적이고 완치율이 높아 여전히 가장 흔하고 선호되는 치료법이기 때문에 선양낭성암 시장을 주도할 것으로 예상됩니다. 선양낭성암은 주로 침샘에 발생하기 때문에 수술이 이 질환의 주요 치료 옵션으로 여겨집니다. 수술 중에는 종양과 암 주변의 정상 조직 일부를 제거합니다. 이 암은 신경을 따라 자주 전이되기 때문에 수술 과정에서 관련된 신경을 확인하는 것이 중요합니다.
또한, 다양한 수술 기법에 대한 여러 임상 시험이 진행 중입니다. 예를 들어, 오하이오 주립대학교 종합 암 센터는 다빈치 로봇 수술 시스템을 사용하여 선양낭성암 치료를 위한 경구 로봇 수술(TORS) 임상 시험을 진행하고 있습니다. 또한, 중등도 또는 고등급 암이나 선양낭성암이 있거나 암이 완전히 제거되지 않은 경우 수술 후 방사선 치료가 권장됩니다. 따라서 위의 요인들을 고려할 때, 해당 부문은 예측 기간 동안 성장할 것으로 예상됩니다.
지역별 시장 점유율
북미는 유명 연구 기관의 존재로 인해 2022년 시장 점유율의 약 39.4%를 차지했습니다.
북미, 특히 미국은 선진 의료 인프라와 새로운 치료법 개발을 위한 연구를 수행하는 유명 연구 기관의 존재로 인해 전 세계 선양낭성암 시장을 주도하고 있습니다. 이 지역의 우수한 의료 시설은 최첨단 치료법에 대한 접근성을 제공하며, 집중적인 인식 개선 캠페인과 정기적인 검진은 조기 발견 및 치료 결과 향상에 기여합니다.
예를 들어, 미국 임상 종양학회(ASCO)에 2022년 발표된 논문에서 미국의 저명한 연구 기관인 텍사스 대학교 MD 앤더슨 암센터는 이 암에 대한 광범위한 연구를 수행했습니다. 이 연구는 NOTCH1 돌연변이 선양낭성암을 표적으로 하는 NOTCH1 억제제 사용을 포함합니다. 이러한 억제제는 시퀀싱 기술과 분자 분석을 통해 설계되었으며, 희귀하고 공격적인 두경부암인 선양낭성암 환자에게 매우 유망한 치료제로 평가됩니다. 따라서 이러한 요인들로 인해 해당 지역 시장은 예측 기간 동안 빠른 속도로 성장할 것으로 예상됩니다.
경쟁 환경
선양낭성암 시장의 주요 글로벌 기업으로는 Ayala Pharmaceuticals, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, OncoMed Pharmaceuticals 등이 있습니다.
COVID-19 영향 분석
COVID-19는 많은 악성 종양의 초기 병기를 악화시키고 예후에 악영향을 미쳤습니다. 하지만 경구용 VEGFR2 TKI인 리보세라닙은 2상 임상 연구에서 재발성 또는 전이성 선양낭성암 환자에게서 유망한 결과를 보였습니다. COVID-19는 암 환자와 암 생존자의 삶의 질과 건강에 광범위한 영향을 미칠 수 있습니다.
더욱이, ACC 환자와 같은 암 환자는 특히 고령, 남성, 기저질환이 많은 경우, 혈액암 환자, 그리고 최근 항암화학요법을 받은 경우 COVID-19 중증화 및 사망 위험이 더 높습니다. 팬데믹 기간 동안 암 검진이 지연되면서 조기 발견이 늦어지고, 진행성 단계에서 진단받는 환자의 비율이 높아지며, 사망률 또한 증가했습니다. ACC 환자는 조기 발견이 질병 예후를 개선하므로 엄격한 추적 관찰을 준수하고 의심스러운 임상 징후가 나타나면 즉시 의료진의 진료를 받아야 합니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 전 세계 선양낭성암 시장에 영향을 미치고 있습니다. 우크라이나 내전으로 의료 서비스 접근성이 저하되면서 선양낭성암 환자들이 필수적인 치료를 받기가 더욱 어려워졌습니다. 치료비 부담 증가와 경제 불안정으로 환자들의 재정적 부담이 가중되면서 의료 서비스 이용이 더욱 어려워졌습니다. 또한, 내전으로 인해 의료 지원을 꺼리는 사람들이 많아 진단과 치료가 지연되는 사례도 발생하고 있습니다.
이러한 장애물들은 전 세계 선양낭성암 시장에 부정적인 영향을 미쳐 예상보다 더딘 성장을 초래했습니다. 하지만 우크라이나에서 보다 효과적인 치료법 개발과 선양낭성암에 대한 인식 제고에 힘쓴다면 시장 성장 잠재력은 여전히 존재합니다. 전쟁이 종식되고 의료 서비스 접근성이 개선됨에 따라 시장은 회복될 것으로 예상됩니다. 그럼에도 불구하고 내전이 시장에 미치는 영향은 여전히 막대하며, 내전으로 인한 문제점과 기회를 해결하기 위한 지속적인 노력이 필요합니다.

발생 부위별
• 침샘
• 눈물샘
• 유방
• 기타
약물 종류별
• 세포독성 약물
• 티로신 키나제 억제제
• 단클론 항체
• 기타
치료법별
• 수술
• 방사선 치료
• 화학 요법
• 표적 치료
유통 채널별
• 병원 약국
• 일반 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2022년 6월 6일, 임상 단계 종양학 회사인 아얄라 제약(Ayala Pharmaceuticals, Inc.)은 소분자 약물 개발 및 상용화에 주력하고 있습니다. 희귀하고 공격적인 암, 특히 유전적으로 정의된 환자 집단을 대상으로 하는 분자 치료제 개발 회사인 엘레바 테라퓨틱스(Elevar Therapeutics, Inc.)는 2상 ACCURACY 연구 결과를 2022년 6월 3일부터 7일까지 미국 일리노이주 시카고에서 개최되는 미국 임상종양학회(ASCO) 연례 회의에서 포스터로 발표할 예정이라고 밝혔습니다.
• 2021년 2월 8일, 엘레바 테라퓨틱스는 보도자료를 통해 미국 식품의약국(FDA)이 희귀 질환인 선양낭성암 치료를 위한 소분자 티로신 키나제 억제제 아파티닙(리보세라닙)에 대해 희귀의약품 지정을 승인했다고 발표했습니다.

보고서 구매 이유:

• 지역, 약물 종류, 치료법, 유통 채널 및 지역별 전 세계 선양낭성암 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위함입니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴하기 위함입니다.

• 모든 세그먼트를 포함한 선양낭성암 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품들을 정리한 제품 맵핑 엑셀 파일.

글로벌 선양낭성암 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
Global Adenoid Cystic Carcinoma Market reached US$ 224.3 million in 2022 and is expected to reach US$ 344.6 million by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030. The trend such as shift towards personalized medicine is expected to dominate the global adenoid cystic carcinoma market.
The global adenoid cystic carcinoma (ACC) market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as usage of targeted therapies, and emerging immunotherapy and RNA therapy options.
Furthermore, rising prevalence of adenoid cystic carcinoma, advancements in diagnostic techniques, increase in focus on research and development activities is driving up the adenoid cystic carcinoma market size. Due to the advancements of diagnostics technologies in these fields resulting improved detection and diagnosis of adenoid cystic carcinoma is seeing an increase in demand from North American regions with significant competitors like Ayala Pharmaceuticals, Amgen, CureVac AG, and others actively operating in the market.
Market Dynamics
The Growing Prevalence of Adenoid Cystic Carcinoma to Drive the Growth of the Adenoid Cystic Carcinoma Market
The rising number of cases of adenoid cystic carcinoma is a key driver driving the adenoid cystic carcinoma market's expansion. This is due to the increase awareness about the disease that has resulted in more number of cases. For instance, according to the American Society of Clinical Oncology (ASCO) report of 2023, about 1300 people are been diagnosed with this cancer every year in U.S.
Moreover, the adenoid cystic carcinoma is mostly prevalent in women accounting 60% of all cases. Because of this increasing occurrence, there has been a greater emphasis on the research and development, with the goal of discovering novel therapeutic options and improving existing medications. Thus, owing to the growing prevalence of these condition to drive the market over the forecast period.
The Increasing Number of Clinical Trials will Drive the Market Growth
The growing number of clinical trials for adenoid cystic carcinoma treatment and diagnosis is a major driver for this market. Clinical trials play a major role in discovering novel treatment and diagnostic options thereby providing a improved patient outcomes. Moreover, the data generated from this clinical trial makes an important gateway in fostering the research, and increasing the international collaboration.
For instance, Memorial Sloan Kettering Cancer Center in collaboration with Merck Sharp & Dohme LLC and Eisai Inc. is conducting a clinical trial that has began on December 2019. The primary objective of this trial is to evaluate the study and safety of drugs such as Lenvatinib and Pembrolizumab in people with advanced Adenoid Cystic Carcinoma (ACC). Currently the trial is phase 2 and the estimated completion of trial is December 2023. Thus, owing to the increasing number of clinical trials the market is expected to drive over the foreseeable future.
The High Cost Associated with Adenoid Cystic Carcinoma Treatment will Hamper the Growth of the Market
Adenoid cystic carcinoma treatment involves surgery, medication such as targeted therapies, that can be relatively expensive. This has resulted in limited access towards advanced treatment for the patient suffering from this condition. For instance, the cost of immunotherapy drugs used in ACC treatment are very costly for many patient, thereby hindering their access to this potentially beneficial treatment option.
Segment Analysis
The global adenoid cystic carcinoma market is segmented based on location, drug class, treatment, distribution channel and region.
Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Adenoid Cystic Carcinoma Market Share
The surgery segment is poised to dominate the adenoid cystic carcinoma market as it remains a common and preferred medical treatment for adenoid cystic carcinomas owing to its effectiveness and better cure for this carcinoma. As adenoid cystic carcinoma mainly affects in the salivary gland, the surgery remains the foremost treatment option for this disease. During surgery their is removal of tumor and some of the healthy tissue around the cancer, as this cancer spreads frequently along the nerves, the surgery becomes an important segment in identifying the nerves involved in it.
Furthermore, many clinical trial are in progress involving different surgery tecniques. For instance, Ohio State University Comprehensive Cancer Center is conducting a clinical trial consisting of transoral robotic surgery (TORS) for treating adenoid cystic carcinoma it uses the the Da Vinci Robotic Surgical System for the surgery. Furthermore, radiation therapy is advised after surgery if there is an intermediate- or high-grade cancer or an adenoid cystic carcinoma, or the cancer was not removed completely. Thus, considering the above factors the segment is expected to grow over the forecast period.
Geographical Penetration
North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Presence of Renowed Research Institutions
North America, particularly the United States, dominates the global adenoid cystic carcinoma market due to its advanced healthcare infrastructure, presence of renowed research institute conducting research for development of novel treatment options. The region's superior medical facilities provide access to cutting-edge therapies, while intensive awareness campaigns and regular screenings contribute to improved early identification and treatment outcomes.
For instance, a 2022 article published in American Society of Clinical Oncology the University of Texas MD Anderson Cancer Center an established research center in U.S. has conducted a extensive research for this carcinoma. The research involves use of NOTCH1 inhibitors that targets NOTCH1-mutant adenoid cystic carcinoma. These inhibitors are designed from sequencing techniques and molecular analysis, that shows immense promise for patients with ACC, a rare and aggressive head and neck cancer. Therefore, owing to the above factors the market is expected to grow at faster rate in this region over the forecast period.
Competitive Landscape
The major global players in the adenoid cystic carcinoma include Ayala Pharmaceuticals, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, and OncoMed Pharmaceuticals and among others.
COVID-19 Impact Analysis
The effect of COVID-19 on ACC has worsened the presenting stage of many malignancies and had a detrimental impact on their prognosis. However, rivoceranib, an oral VEGFR2 TKI, showed promising results in individuals with recurrent or metastatic ACC in a phase 2 study. COVID-19 may have an extensive effect on the standard of life and well-being of cancer patients and survivors.
Moreover, cancer patients, such as those with ACC, are more likely to develop severe COVID-19 and die from it, especially if they are older, male, have a larger number of comorbidities, have hematologic malignancies, and have just received chemotherapy. Cancer screening delays during the pandemic led to delayed detection, a higher proportion of patients being diagnosed at an advanced stage, and a higher death rate. ACC patients must adhere to strict follow-up and seek medical attention for any suspicious clinical signs since early detection improves illness prognosis.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is having impact on the global adenoid cystic carcinoma market. The conflict has decreased access to healthcare services in Ukraine, making it harder for adenoid cystic carcinoma patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help in the midst of the conflict.
These obstacles have had a detrimental impact on the worldwide adenoid cystic carcinoma market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving adenoid cystic carcinoma awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.
By Site
• Salivary Gland
• Lacrimal Gland
• Breast
• Others
By Drug Class
• Cytotoxic Drugs
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• Others
By Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On June 6, 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, stated that data from the Phase 2 ACCURACY study will be presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held on June 3-7, 2022, in Chicago, Illinois.
• On February 8, 2021, Elevar Therapeutics, Inc stated in a press release that the FDA has given Orphan Drug Designation to the small molecule tyrosine kinase inhibitor apatinib (Rivoceranib) for the treatment of the rare disease adenoid cystic carcinoma.
Why Purchase the Report?
• To visualize the global adenoid cystic carcinoma market segmentation based on location, drug class, treatment, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of adenoid cystic carcinoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as excel consisting of key products of all the major players.
The global adenoid cystic carcinoma market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet By Site
3.2. Snippet by Drug Class
3.3. Snippet by Treatment
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Growing Prevalence of Adenoid Cystic Carcinoma
4.1.1.2. The Increasing Number of Clinical Trials
4.1.2. Restraints
4.1.2.1. The High Cost Associated with Adenoid Cystic Carcinoma Treatment
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Personalized Medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Site
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
7.1.2. Market Attractiveness Index, By Site
7.2. Salivary Gland*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lacrimal Gland
7.4. Breast
7.5. Others
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Cytotoxic Drugs*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Tyrosine Kinase Inhibitors
8.4. Monoclonal Antibodies
8.5. Others
9. By Treatment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment
9.2. Surgery*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Radiation Therapy
9.4. Chemotherapy
9.5. Targeted Therapy
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Site
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Ayala Pharmaceuticals*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Amgen
13.3. CureVac AG
13.4. Elevar Therapeutics
13.5. Actuate Therapeutics
13.6. Prelude Therapeutics
13.7. Merck Sharp & Dohme Corp.
13.8. Lilly USA, LLC
13.9. Celgene Corporation
13.10. OncoMed Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Ayala Pharmaceuticals, 4.	Key Developments, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, OncoMed Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Adenoid Cystic Carcinoma Market Value, By Site, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Adenoid Cystic Carcinoma Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Adenoid Cystic Carcinoma Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Adenoid Cystic Carcinoma Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Adenoid Cystic Carcinoma Market Value, By Site, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 8 Global Adenoid Cystic Carcinoma Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 10 Global Adenoid Cystic Carcinoma Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 12 Global Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Adenoid Cystic Carcinoma Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Adenoid Cystic Carcinoma Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 17 North America Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 North America Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 19 North America Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Adenoid Cystic Carcinoma Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 22 South America Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 23 South America Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 24 South America Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Adenoid Cystic Carcinoma Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 27 Europe Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 28 Europe Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 29 Europe Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Adenoid Cystic Carcinoma Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Adenoid Cystic Carcinoma Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Adenoid Cystic Carcinoma Market Value, By Site, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Adenoid Cystic Carcinoma Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Adenoid Cystic Carcinoma Market Value, By Treatment, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Adenoid Cystic Carcinoma Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Ayala Pharmaceuticals: Overview

Table 41 Ayala Pharmaceuticals: Product Portfolio

Table 42 Ayala Pharmaceuticals: Key Developments

Table 43 Amgen: Overview

Table 44 Amgen: Product Portfolio

Table 45 Amgen: Key Developments

Table 46 CureVac AG: Overview

Table 47 CureVac AG: Product Portfolio

Table 48 CureVac AG: Key Developments

Table 49 Elevar Therapeutics: Overview

Table 50 Elevar Therapeutics: Product Portfolio

Table 51 Elevar Therapeutics: Key Developments

Table 52 Actuate Therapeutics: Overview

Table 53 Actuate Therapeutics: Product Portfolio

Table 54 Actuate Therapeutics: Key Developments

Table 55 Prelude Therapeutics: Overview

Table 56 Prelude Therapeutics: Product Portfolio

Table 57 Prelude Therapeutics: Key Developments

Table 58 Merck Sharp & Dohme Corp.: Overview

Table 59 Merck Sharp & Dohme Corp.: Product Portfolio

Table 60 Merck Sharp & Dohme Corp.: Key Developments

Table 61 Lilly USA, LLC: Overview

Table 62 Lilly USA, LLC: Product Portfolio

Table 63 Lilly USA, LLC: Key Developments

Table 64 Celgene Corporation: Overview

Table 65 Celgene Corporation: Product Portfolio

Table 66 Celgene Corporation: Key Developments

Table 67 OncoMed Pharmaceuticals: Overview

Table 68 OncoMed Pharmaceuticals: Product Portfolio

Table 69 OncoMed Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 2 Global Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 3 Global Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 5 Global Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Adenoid Cystic Carcinoma Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Adenoid Cystic Carcinoma Market Y-o-Y Growth, By Site, 2022-2030 (%)

Figure 8 Salivary Gland Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 9 Lacrimal Gland Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 10 Breast Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 11 Others Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 12 Global Adenoid Cystic Carcinoma Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 13 Cytotoxic Drugs Drug Class in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 14 Tyrosine Kinase Inhibitors Drug Class in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 15 Monoclonal Antibodies Drug Class in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 16 Others Drug Class in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 17 Global Adenoid Cystic Carcinoma Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 18 Surgery Treatment in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 19 Radiation Therapy Treatment in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 20 Chemotherapy Treatment in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 21 Targeted Therapy Treatment in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 22 Global Adenoid Cystic Carcinoma Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospital Pharmacies Distribution Channel in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 24 Retail Pharmacies Distribution Channel in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 25 Online Pharmacies Distribution Channel in Global Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 26 Global Adenoid Cystic Carcinoma Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 28 Asia-Pacific Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 29 Europe Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 30 South America Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 31 Middle East and Africa Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 32 North America Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 33 North America Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 34 North America Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 35 North America Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 36 North America Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 North America Adenoid Cystic Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 38 South America Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 39 South America Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 40 South America Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 41 South America Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 42 South America Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 South America Adenoid Cystic Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 44 Europe Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 45 Europe Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 46 Europe Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 47 Europe Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 48 Europe Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Europe Adenoid Cystic Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 50 Asia-Pacific Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 51 Asia-Pacific Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 52 Asia-Pacific Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 53 Asia-Pacific Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 54 Asia-Pacific Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Asia-Pacific Adenoid Cystic Carcinoma Market Share, By Country, 2022 & 2030 (%)

Figure 56 Middle East & Africa Adenoid Cystic Carcinoma Market Value, 2021-2030 (US$ Million)

Figure 57 Middle East & Africa Adenoid Cystic Carcinoma Market Share, By Site, 2022 & 2030 (%)

Figure 58 Middle East & Africa Adenoid Cystic Carcinoma Market Share, By Drug Class, 2022 & 2030 (%)

Figure 59 Middle East & Africa Adenoid Cystic Carcinoma Market Share, By Treatment, 2022 & 2030 (%)

Figure 60 Middle East & Africa Adenoid Cystic Carcinoma Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 61 Ayala Pharmaceuticals: Financials

Figure 62 Amgen: Financials

Figure 63 CureVac AG: Financials

Figure 64 Elevar Therapeutics: Financials

Figure 65 Actuate Therapeutics: Financials

Figure 66 Prelude Therapeutics: Financials

Figure 67 Merck Sharp & Dohme Corp.: Financials

Figure 68 Lilly USA, LLC: Financials

Figure 69 Celgene Corporation: Financials

Figure 70 OncoMed Pharmaceuticals: Financials

세계 선양낭성암 시장 – 2023-2030

Global Adenoid Cystic Carcinoma Market - 2023-2030